Nicole Wolf currently works as a child neurologist at the Amsterdam Leukodystrophy Center, Amsterdam UMC with a focus on inherited white matter and neurometabolic disorders. Since 2015 she is also a member of the scientific advisory board of the European Leukodystrophy Association (ELA).

“My goal is to make more effective treatments available for patients with leukodystrophies than we have now.”

Last week, Wolf spoke in her inaugural lecture about genetic diseases of the brain white matter, leukodystrophies. Most often, these conditions lead to neurological decline and often death. Targeted therapies are almost non-existent, but this is slowly changing. Different treatments are becoming available, often in only a few centers worldwide, and sometimes even as a small n=1 trial for one patient. How lessons can be learned from a particular disease course and how the effectiveness of new therapies can be measured in small groups are some of the questions that Wolf tries to answer.